Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(1):9-11; doi:10.1093/jnci/95.1.9
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Randal, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Randal, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 1, 9-11, January 1, 2003
© 2003 Oxford University Press

NEWS

NIH Workshop Tries to Create Consensus on HRT Use

Judith Randal

The first 10% of the full text of this article appears below.

A little of the dust has settled since the July 9 news about the use of combined hormone replacement therapy (HRT) during and after menopause: Long-term use may increase a woman’s chances of becoming chronically ill. (See News, August 7, p. 1116.)

But that has not dampened interest in the landmark study that yielded those results—a 16,608-woman randomized trial that was funded by the National Institutes of Health as part of its Women’s Health Initiative (WHI). The trial pitted Prempro (a combined estrogen-progestin pill made by Wyeth) against a placebo. When NIH held a workshop on its campus in October in reaction to the study, some 500 scientists, clinicians, women’s health advocates, regulatory officials and others showed up to discuss its ramifications.

(The workshop dealt only with issues . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?